Clinical Trial Update: Genetic Predictors of Benefit to Pembrolizumab [Phase 2]

View source ↗

Summary

Phase 2 trial investigating genetic predictors of benefit to pembrolizumab in non-small cell lung carcinoma; the study was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Columbia University | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: TERMINATED | Results posted: 2023-07-24